Wearable Integrated Sparse-SPECT for Cancer Radiotherapy
Radiopharmaceutical therapy (RPT) has recently shown promise in the treatment of neuroendocrine and prostate cancer, giving hope to late stage metastatic cancer patients that currently have very few treatment options. RPT involves conjugating a radioisotope to a cancer specific molecule, which is subsequently intravenously administered to selectively target cancer cells anywhere in the body while sparing most normal tissues. Currently, there is no method for continuous, real-time monitoring of the biokinetics of this radiopharmaceutical to optimize and maximize the radiation dose to the tumors while ensuring minimal dose is delivered to healthy organs to prevent toxicity. I am working on developing a wearable network of single gamma photon-sensitive ICs and sparse dose reconstruction methodology to enable a high temporal resolution imaging system for RPT personalization.
Expected Graduation Date:
May, 2027
